List of Excipients in Branded Drug ONDANSETRON HYDROCHLORIDE AND DEXTROSE

Generic Drugs Containing ONDANSETRON HYDROCHLORIDE AND DEXTROSE

Company	Ingredient	NDC	Excipient
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	CITRIC ACID MONOHYDRATE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	DEXTROSE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	SODIUM CITRATE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	WATER

What are the Most Frequently-Used Excipients in ONDANSETRON HYDROCHLORIDE AND DEXTROSE?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	DEXTROSE
1	SODIUM CITRATE
1	WATER

Ondansetron Hydrochloride and Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 29, 2026

Ondansetron hydrochloride and dextrose is primarily an intravenous ready-to-use formulation opportunity rather than a new chemical entity opportunity. The commercial value lies in reducing pharmacy compounding, improving handling, extending in-use convenience, and meeting hospital demand for standardized antiemetic doses. Ondansetron’s core composition and major use patents are expired in the United States, so differentiation depends on formulation execution, container technology, supply reliability, regulatory efficiency, and contracting.

What is ondansetron hydrochloride and dextrose?

Ondansetron hydrochloride is a selective 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. Dextrose is used as the intravenous diluent, commonly as a 5% dextrose solution.

The product may be supplied as:

• A ready-to-use premixed intravenous bag
• A pharmacy admixture prepared by diluting ondansetron injection into 5% dextrose
• A small-volume container or syringe intended for hospital administration
• A compounded or contract-manufactured presentation for institutional use

The combination is generally a formulation pairing rather than a novel fixed-dose pharmaceutical combination. Dextrose does not create a new pharmacologic mechanism. Its role is to provide vehicle, tonicity, and a standard intravenous administration medium.

FDA-approved ondansetron injection labeling identifies dilution in compatible intravenous solutions, including 5% dextrose injection, subject to concentration, storage, and administration conditions specified in the applicable label.[1]

What excipients are used in ondansetron hydrochloride and dextrose injection?

The central excipient system is usually simple:

Component	Primary function	Key development issue
Ondansetron hydrochloride dihydrate or equivalent	Active pharmaceutical ingredient	Assay, impurities, pH stability
Dextrose monohydrate	Tonicity agent and vehicle component	Degradation, color, concentration control
Water for injection	Solvent	Bioburden, endotoxin, conductivity
pH-adjusting agents	Control solution pH	Local concentration, compatibility, extractables
Container-closure system	Sterility and shelf life	Adsorption, leachables, oxygen transmission

A commercial formulation should minimize unnecessary excipients. Each added buffer, chelator, antioxidant, surfactant, or antimicrobial preservative creates additional regulatory, compatibility, and extractables work.

Dextrose concentration and tonicity

Dextrose concentration affects:

• Osmolality
• Intravenous tolerability
• Chemical stability
• Risk of precipitation or crystallization
• Container compatibility
• Labeling and administration instructions

A 5% dextrose vehicle is familiar to hospitals and supported by extensive clinical use. A manufacturer considering a different dextrose concentration would need a clear commercial or technical reason, such as a smaller fluid burden, specific pediatric use, or improved stability.

pH control

Ondansetron hydrochloride injection is an aqueous acidic formulation. pH affects:

• Ondansetron degradation
• Formation of related substances
• Visual appearance
• Container interaction
• Compatibility with co-administered solutions

A narrow pH target can improve lot consistency, but aggressive buffering may reduce flexibility during sterilization and storage. The formulation should be developed around real-time stability data rather than a broad nominal pH range.

Preservative strategy

A preservative-free single-dose presentation is generally better aligned with hospital intravenous use. Preservatives can complicate neonatal, pediatric, oncology, and perioperative positioning. A multidose presentation may reduce packaging cost but creates additional sterility, antimicrobial effectiveness, labeling, and handling requirements.

What formulation patents protect ondansetron hydrochloride and dextrose?

The core ondansetron molecule, major therapeutic uses, and original branded injectable products are not protected by meaningful U.S. composition-of-matter exclusivity. The commercial opportunity is therefore predominantly generic or reformulation-based.

IP category	Likely status in the United States	Commercial implication
Ondansetron active ingredient	Expired	No meaningful composition-of-matter barrier
Original antiemetic use patents	Expired or no longer commercially blocking	Generic entry is established
Conventional ondansetron injection	Generally mature generic field	Price and supply competition are significant
Ondansetron in dextrose premix	Protection depends on specific product, container, and claims	Product-specific freedom-to-operate review remains necessary
Manufacturing process claims	May exist at individual suppliers	API and sterile manufacturing controls are important
Device or container claims	Potentially relevant	Ready-to-use bags, syringes, and connectors require review
New delivery systems	Potentially patentable	Commercial value depends on clinical or operational advantage

Patent risk should be assessed against the exact presentation, concentration, container, closure, manufacturing process, and proposed labeling. A broad search for “ondansetron” is insufficient because relevant claims may be directed to sterile bags, multilayer films, terminal sterilization, oxygen control, or combination packaging.

When does ondansetron lose exclusivity?

Ondansetron lost its principal U.S. exclusivity years ago. The original Zofran product was commercialized by GlaxoSmithKline, formerly Glaxo Wellcome, and generic ondansetron products entered the U.S. market after expiration of the principal patent and regulatory exclusivities.

The practical exclusivity position is:

Exclusivity type	Current commercial position
Chemical composition exclusivity	Expired
Original branded injection exclusivity	Expired
Conventional generic injectable market	Open
Pediatric or indication-specific historical exclusivity	Expired
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Possible only if supported by a qualifying new product

A new ondansetron hydrochloride and dextrose product would not normally receive meaningful new-drug exclusivity merely because it uses a ready-to-use dextrose vehicle. A new 505(b)(2) strategy would require a clinically and regulatorily meaningful difference, such as a new route, delivery system, dosing profile, or clinically relevant formulation benefit.

What is the FDA regulatory status of ondansetron hydrochloride and dextrose?

Ondansetron hydrochloride injection is an established FDA-approved product category. A conventional generic can generally be pursued through an abbreviated new drug application if it demonstrates pharmaceutical equivalence and bioequivalence or otherwise satisfies the applicable injectable-product requirements.

The likely regulatory pathways are:

ANDA pathway

The ANDA pathway is appropriate when the proposed product matches the reference product in relevant respects, including:

• Active ingredient
• Route of administration
• Dosage form
• Strength
• Pharmaceutical equivalence
• Quality attributes
• Labeling, subject to permissible differences

For a sterile injectable, the principal burden is usually product quality rather than conventional pharmacokinetic bioequivalence. Critical areas include sterility assurance, particulate matter, bacterial endotoxins, container closure integrity, extractables and leachables, stability, and manufacturing process validation.

505(b)(2) pathway

A 505(b)(2) application may be relevant for:

• A novel ready-to-administer presentation
• A new concentration
• A new container or delivery device
• A changed route or administration method
• A clinically meaningful reduction in preparation steps

The pathway is more expensive and slower than a conventional ANDA. Its commercial rationale depends on whether the product obtains a meaningful label, hospital-use, or contracting advantage.

Drug shortage and hospital supply opportunities

Ondansetron injection has been affected periodically by injectable-drug supply constraints across the industry. FDA’s Drug Shortages database should be reviewed before launch and during commercialization because shortage status can affect procurement, customer switching, and regulatory prioritization.[2] A manufacturer with reliable sterile capacity may obtain contracts even when the product is therapeutically interchangeable with numerous generics.

How many patents cover ondansetron hydrochloride and dextrose?

No single number can be assigned without defining the jurisdiction, product presentation, and patent database. The practical U.S. landscape is mature:

• The active ingredient has no meaningful live composition patent blocking conventional entry.
• Original branded ondansetron patents are historical rather than current commercial barriers.
• Potentially relevant live rights may concern specific formulations, containers, manufacturing methods, or delivery systems.
• The Orange Book should be searched for the exact reference-listed drug and product presentation before filing.[3]

An Orange Book listing does not capture every possible patent risk. It generally does not provide a complete record of third-party process patents, supplier patents, packaging rights, or foreign-country rights.

What is the Orange Book status of ondansetron injection?

Ondansetron injection products and related dosage forms have been approved through both innovator and generic pathways. For a proposed generic, the relevant analysis should cover:

1. The reference-listed drug selected for the ANDA.
2. Current Orange Book patent listings for that reference product.
3. Regulatory exclusivity codes.
4. Paragraph IV certification requirements.
5. Any labeling carve-outs required for protected indications.
6. Product-specific differences between ampoules, vials, bags, and syringes.

A generic applicant should not assume that the absence of a listed patent eliminates all litigation risk. The applicant must also review product-specific patents outside the Orange Book and assess whether its manufacturing process or packaging falls within third-party claims.

Are Paragraph IV challenges relevant?

Paragraph IV litigation risk is limited for the mature conventional ondansetron market because the principal branded exclusivities have expired. It can still arise if:

• A new reference product has listed formulation or delivery patents.
• A reformulated ondansetron product receives new regulatory exclusivity.
• A generic applicant challenges a later-listed patent.
• The proposed product uses a patented container, premix technology, or administration device.

A conventional ondansetron hydrochloride injection applicant is more likely to encounter competitive filing risk, manufacturing inspections, and procurement pressure than substantial Orange Book litigation.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are operational.

Sterile manufacturing

A commercial product requires validated controls for:

• Raw-material bioburden
• Water-for-injection quality
• Solution compounding
• Sterile filtration or terminal sterilization
• Aseptic filling, where applicable
• Container closure integrity
• Particulate matter
• Endotoxin control
• Visual inspection
• Stability through labeled shelf life

Injectable manufacturing failures can result in recalls, supply interruptions, or FDA enforcement even where the product has no meaningful patent barrier.

Dextrose degradation

Dextrose can participate in degradation pathways under heat and storage stress. Development work should assess:

• Color formation
• pH drift
• Related substances
• Sterilization impact
• Oxygen exposure
• Light sensitivity
• Interaction with the container film
• Compatibility after dilution or simulated administration

Container technology

The container may create more differentiation than the liquid formula. Candidate systems include:

• Polyolefin bags
• Multilayer plastic bags
• Glass bottles
• Single-dose syringes
• Ready-to-use infusion containers
• Dual-chamber or break-seal systems

Container selection affects logistics, breakage, overwrap requirements, extractables, leachables, port compatibility, and hospital workflow. Claims directed to a specific bag structure or closure system may create patent exposure even when the drug formulation itself is unprotected.

What commercial opportunities exist for ondansetron hydrochloride and dextrose?

The strongest opportunity is a hospital-focused ready-to-use product with a reliable supply profile.

Ready-to-administer premix

A premixed product can reduce:

• Pharmacy preparation time
• Dose calculation errors
• Manipulation of sterile containers
• Waste from partial vials
• Nursing workflow burden
• Exposure to compounding interruptions

Hospitals may accept a higher unit price than a vial if the product reduces labor and preparation costs. The economic case should quantify pharmacy labor, discarded volume, procurement complexity, and medication-error risk.

Small-volume oncology and perioperative products

Potential customer segments include:

• Oncology infusion centers
• Ambulatory surgery centers
• Hospital operating rooms
• Emergency departments
• Pediatric hospitals
• Infusion clinics
• Contract pharmacy and institutional buyers

A small-volume, preservative-free product may be attractive where fluid volume and rapid administration matter.

Supply-reliable generic positioning

The injectable market is sensitive to shortages. A supplier with multiple API sources, redundant fill-finish capacity, and validated backup packaging can compete on continuity rather than price alone.

Private-label and contract manufacturing

Opportunities include:

• Private-label hospital products
• Regional generic distributors
• Group purchasing organization contracts
• Contract manufacturing for branded generic companies
• Export products for jurisdictions using dextrose premixes

Contract manufacturing can reduce commercial overhead but may compress margins and transfer customer ownership to the sponsor.

Geographic expansion

The product is most readily commercialized in markets with:

• Established ondansetron injection demand
• Hospital-based generic procurement
• Recognized dextrose infusion standards
• Mature sterile manufacturing regulation
• Public or private tenders for injectable medicines

U.S. approval does not automatically establish foreign market access. Countries may differ in permitted concentrations, container types, stability data, labeling, and pharmacopoeial requirements.

How does ondansetron hydrochloride and dextrose compare with ondansetron in saline?

Factor	Ondansetron in dextrose	Ondansetron in saline
Hospital familiarity	High	High
Use in fluid-sensitive patients	Less attractive if dextrose load matters	May be preferred in some settings
Tonicity management	Straightforward at standard concentrations	Straightforward
Dextrose-related degradation	Requires specific stability controls	Avoids dextrose degradation pathways
Procurement value	Strong where D5W is standard	Strong where saline is preferred
Market differentiation	Premix and packaging driven	Premix and packaging driven
Clinical substitution	Depends on label and institution	Depends on label and institution

A dual-product strategy using both dextrose and saline vehicles can broaden hospital coverage, but it increases validation, inventory, labeling, and manufacturing complexity.

How strong is the patent estate for ondansetron hydrochloride and dextrose?

The patent estate is weak for the basic drug-and-diluent concept and potentially stronger only for a narrowly defined product architecture.

Patent dimension	Strength assessment
Ondansetron molecule	Weak as a current barrier; historical rights expired
Standard injectable solution	Weak to moderate, depending on specific claims
Dextrose vehicle	Weak for conventional concentrations
Premixed ready-to-use bag	Moderate if protected by specific formulation or container claims
Sterilization process	Variable; requires claim-by-claim analysis
Delivery device	Potentially moderate to strong for proprietary systems
Manufacturing know-how	Often commercially important even without patent protection
Foreign patent coverage	Country-specific and potentially uneven

Trade secrets may matter more than patents for impurity control, sterilization parameters, filling yields, and container compatibility. A robust freedom-to-operate program should cover both patent claims and confidential manufacturing practices.

What generic launch scenarios exist?

Low-cost vial launch

This approach minimizes development and packaging cost but faces intense competition. It is suitable for a company with existing sterile injectable infrastructure and established hospital distribution.

Ready-to-use bag launch

This approach requires greater packaging investment but can command a workflow premium. The product should be supported by hospital-use data, pharmacy economics, and a clear administration advantage.

Prefilled syringe launch

A syringe may target operating rooms, emergency departments, and ambulatory settings. The principal challenges are device compatibility, dose accuracy, extractables and leachables, stability, and customer preference.

Shortage-response launch

A manufacturer can pursue commercial entry where supply is constrained, but the strategy depends on regulatory timing, API availability, FDA inspection readiness, and the duration of the market shortage. Shortage-driven demand can fall quickly once incumbent supply returns.

What licensing deals are relevant?

No major active license is generally required to commercialize conventional ondansetron hydrochloride and dextrose in the United States because the foundational branded rights have expired. Licensing may still be useful for:

• Ready-to-use bag technology
• Proprietary sterile filling systems
• Container-closure platforms
• Hospital distribution
• Foreign market rights
• Contract manufacturing capacity
• Alternative API sources

A licensing transaction should distinguish patent rights from manufacturing services. A technology license may provide freedom to use a packaging platform but not eliminate obligations relating to API, process, regulatory data, or third-party suppliers.

What litigation affects the product?

The principal litigation exposure for a conventional product is likely to involve:

• ANDA patent litigation tied to a specific reference product
• Contract disputes over supply
• Product liability claims
• Sterility or particulate recalls
• Trade-secret disputes involving manufacturing
• Patent disputes over packaging or administration devices

Historical ondansetron patent litigation is less relevant to present commercial entry than product-specific Orange Book review and current sterile manufacturing compliance. Litigation exposure increases when the applicant departs from a conventional vial formulation or adopts proprietary premix packaging.

Key Takeaways

• Ondansetron hydrochloride and dextrose is a mature generic opportunity with limited core patent protection.
• The strongest commercial concept is a preservative-free, ready-to-use intravenous presentation.
• Dextrose concentration, pH, sterilization, oxygen exposure, and container compatibility are the principal formulation variables.
• A conventional product is generally suited to an ANDA strategy; novel devices or delivery systems may support a 505(b)(2) approach.
• Paragraph IV risk is limited for the basic product but can arise from later-listed formulation, container, or device patents.
• The Orange Book is necessary but not sufficient for freedom-to-operate analysis.
• Commercial differentiation depends on hospital workflow, shortage resilience, packaging, contract access, and sterile manufacturing reliability.
• Biosimilar risk is not relevant because ondansetron hydrochloride is a small-molecule drug, not a biologic.
• Manufacturing know-how and container technology may have greater commercial value than composition patents.
• A saline formulation may be a useful portfolio complement but increases development and supply-chain complexity.

Frequently Asked Questions

Is ondansetron hydrochloride and dextrose a new combination drug?

Usually no. It is generally an ondansetron hydrochloride injectable formulation using dextrose as the vehicle or diluent, rather than a new pharmacologic combination.

Can a company patent a new ondansetron and dextrose formulation?

Potentially, but only if the formulation satisfies patentability requirements such as novelty and nonobviousness. A conventional ondansetron concentration in standard dextrose is unlikely to support strong broad claims.

Does ondansetron hydrochloride and dextrose require a biosimilar application?

No. Ondansetron hydrochloride is a small-molecule drug. The relevant U.S. pathways are generally an ANDA or, for certain differentiated products, a 505(b)(2) application.

What is the best commercial package for hospital buyers?

A preservative-free, single-dose, ready-to-administer container with reliable stability and compatibility data is the strongest general commercial proposition. The optimal size depends on institutional dosing and procurement requirements.

Is the dextrose vehicle itself a significant patent barrier?

Not ordinarily. The greater risks arise from specific container systems, premix manufacturing methods, delivery devices, or third-party formulation claims.

References

1. U.S. Food and Drug Administration. (2024). Ondansetron hydrochloride injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). FDA drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. Center for Drug Evaluation and Research.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: Container closure systems for packaging human drugs and biologics.
6. U.S. Food and Drug Administration. (2024). Product-specific guidance for generic drug development. Center for Drug Evaluation and Research.